Synthesis and characterization of HPMA copolymer-aminopropylgeldanamycin conjugates

被引:42
作者
Kasuya, Y
Lu, ZR
Kopecková, P
Minko, T
Tabibi, SE
Kopecek, J
机构
[1] Univ Utah, Dept Pharmaceut & Pharmaceut Chem, CCCD, Salt Lake City, UT 84112 USA
[2] Univ Utah, Dept Bioengn, Salt Lake City, UT 84112 USA
[3] NCI, Pharmaceut Resources Branch, NIH, Bethesda, MD 20892 USA
关键词
geldanamycin; HPMA copolymer; ovarian carcinoma; heat shock protein; drug delivery system;
D O I
10.1016/S0168-3659(01)00318-2
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Geldanamycin (GDM) is a benzoquinone ansamycin antibiotic with anticancer activity. The use of drug delivery systems based on N-(2-hydroxypropyl)methacrylamide (HPMA) copolymers containing lysosomally degradable oligopeptide (GFLG) spacers results in an increased therapeutic efficacy of anticancer drugs. The objective of this study was to synthesize HPMA copolymer-GDM conjugates with anticancer activity and reduced toxic side-effect of the compound. 17-(3-Aminopropylamino)-17-demethoxygeldanamycin (AP-GDM) was synthesized and converted into a polymerizable GDM derivative, N-methacryloylglycylphenytalanylglycyl-17-(3-aminopropylamino)-17-demethoxygeldanamycin [MA-GFLG-(AP-GDM)]. The structures of AP-GDM and MA-GFLG-(AP-GDM) were validated by mass spectroscopy, elemental analysis, and two-dimensional nuclear magnetic resonance. MA-GFLG-(AP-GDM) was copolymerized with HPMA and N-methacryloyglycylglycine p-nitrophenylester by radical precipitation polymerization, Water-soluble HPMA copolymer-AP-GDM conjugates (M-c = 16 kDa) were obtained. Monoclonal antibody OV-TL16. which recognizes the OA-3 antigen expressed on the OVCAR-3 human ovarian carcinoma cell line, was optionally attached to the HPMA copolymer-AP-GDM conjugate. Cytotoxicity of polymer-bound AP-GDM (both targeted and non-targeted) was determined using OVCAR-3 and another human ovarian carcinoma cell line, A2780, The HPMA copolymer-AP-GDM conjugate was cytotoxic toward A2780 cells. Attachment of OV-TL16 antibody enhanced cytotoxicity of the conjugate toward OVCAR-3 cells. (C) 2001 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:203 / 211
页数:9
相关论文
共 42 条
[31]  
RIHOVA B, 1985, Journal of Controlled Release, V2, P289
[32]  
Sasaki K, 1970, J Am Chem Soc, V92, P7591, DOI 10.1021/ja00729a018
[33]   The Hsp90 complex - A super-chaperone machine as a novel drug target [J].
Scheibel, T ;
Buchner, J .
BIOCHEMICAL PHARMACOLOGY, 1998, 56 (06) :675-682
[34]   ERBB-2 ONCOGENE INHIBITION BY GELDANAMYCIN DERIVATIVES - SYNTHESIS, MECHANISM OF ACTION, AND STRUCTURE-ACTIVITY-RELATIONSHIPS [J].
SCHNUR, RC ;
CORMAN, ML ;
GALLASCHUN, RJ ;
COOPER, BA ;
DEE, MF ;
DOTY, JL ;
MUZZI, ML ;
DIORIO, CI ;
BARBACCI, EG ;
MILLER, PE ;
POLLACK, VA ;
SAVAGE, DM ;
SLOAN, DE ;
PUSTILNIK, LR ;
MOYER, JD ;
MOYER, MP .
JOURNAL OF MEDICINAL CHEMISTRY, 1995, 38 (19) :3813-3820
[35]   INHIBITION OF THE ONCOGENE PRODUCT P185(ERBB-2) IN-VITRO AND IN-VIVO BY GELDANAMYCIN AND DIHYDROGELDANAMYCIN DERIVATIVES [J].
SCHNUR, RC ;
CORMAN, ML ;
GALLASCHUN, RJ ;
COOPER, BA ;
DEE, MF ;
DOTY, JL ;
MUZZI, ML ;
MOYER, JD ;
DIORIO, CI ;
BARBACCI, EG ;
MILLER, PE ;
OBRIEN, AT ;
MORIN, MJ ;
FOSTER, BA ;
POLLACK, VA ;
SAVAGE, DM ;
SLOAN, DE ;
PUSTILNIK, LR ;
MOYER, MP .
JOURNAL OF MEDICINAL CHEMISTRY, 1995, 38 (19) :3806-3812
[36]   The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin [J].
Schulte, TW ;
Neckers, LM .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1998, 42 (04) :273-279
[37]   DISRUPTION OF THE RAF-1-HSP90 MOLECULAR-COMPLEX RESULTS IN DESTABILIZATION OF RAF-1 AND LOSS OF RAF-1-RAS ASSOCIATION [J].
SCHULTE, TW ;
BLAGOSKLONNY, MV ;
INGUI, C ;
NECKERS, L .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (41) :24585-24588
[38]   EFFECT OF MOLECULAR-WEIGHT (MBARW) OF N-(2-HYDROXYPROPYL)METHACRYLAMIDE COPOLYMERS ON BODY DISTRIBUTION AND RATE OF EXCRETION AFTER SUBCUTANEOUS, INTRAPERITONEAL, AND INTRAVENOUS ADMINISTRATION TO RATS [J].
SEYMOUR, LW ;
DUNCAN, R ;
STROHALM, J ;
KOPECEK, J .
JOURNAL OF BIOMEDICAL MATERIALS RESEARCH, 1987, 21 (11) :1341-1358
[39]   NEW TYPES OF SYNTHETIC INFUSION SOLUTIONS .3. ELIMINATION AND RETENTION OF POLY[N-(2-HYDROXYPROPYL)METHACRYLAMIDE]IN A TEST ORGANISM [J].
SPRINCL, L ;
EXNER, J ;
STERBA, O ;
KOPECEK, J .
JOURNAL OF BIOMEDICAL MATERIALS RESEARCH, 1976, 10 (06) :953-963
[40]   PRECLINICAL PHARMACOLOGICAL EVALUATION OF GELDANAMYCIN AS AN ANTITUMOR AGENT [J].
SUPKO, JG ;
HICKMAN, RL ;
GREVER, MR ;
MALSPEIS, L .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1995, 36 (04) :305-315